XZXiaosong Zhong

Xiaosong Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaosong Zhong has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Can Zhang

    Department of the Clinical Center of Gene and Cell Engineering, Beijing Shijitan Hospital Capital Medical University Beijing China

    5 shared publications
  • Chang Xu

    Department of the Clinical Center of Gene and Cell Engineering, Beijing Shijitan Hospital Capital Medical University Beijing China

    5 shared publications
  • Yue Bai

    Department of the Clinical Center of Gene and Cell Engineering, Beijing Shijitan Hospital Capital Medical University Beijing China

    5 shared publications
  • Zhijing An

    Department of the Clinical Center of Gene and Cell Engineering, Beijing Shijitan Hospital Capital Medical University Beijing China

    5 shared publications
  • Fang Wang

    Department of the Clinical Center of Gene and Cell Engineering, Beijing Shijitan Hospital Capital Medical University Beijing China

    3 shared publications
  • Aiqin Gu

    The Clinical Center of Gene and Cell Engineering, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

    2 shared publications

Latest Publications

  • Gastrodin synergistically increases migration of interleukin‐13 receptor α2 chimeric antigen receptor T cell to the brain against glioblastoma multiforme: A preclinical study

    by Shuai Huang, Yue Bai, Zhijing An, Chang Xu, Can Zhang, Fang Wang, Chunlong Zhong, Xiaosong Zhong

    Therapy with chimeric antigen receptor T (CAR‐T) cells involves using reformative T lymphocytes that have three domains, antigen recognition, transmembrane, and costimulating to achieve the therapeutic purpose. CAR‐T therapy on malignant hematologic has been successful; however, its effectiveness in patients with solid tumors is still limited. Few studies exist confirming the efficacy of natural products on the function of CAR‐T cells. The purpose of this study is to assess the effect of gastrodin (GAS) on CAR‐T cells that target interleukin‐13 receptor α2 antigen (IL‐13Rα2 CAR‐T) in the brain against glioblastoma multiforme. Migration of IL‐13Rα2 CAR‐T was evaluated using the Transwell assay. The effects of GAS on IL‐13Rα2 CAR‐T cells were assessed both in vitro and situ glioblastoma models. The cytoskeleton was stained with Fluorescein 5‐isothiocyanate (FITC)‐phalloidin. Cytokines expression in cells was determined by flow cytometry and ELISA assay. Western blotting was used to detect the S1P1 expression, and quantitative PCR assay was used to determine the IL‐13Rα2 gene level. GAS increased the migratory and destructive capacity of IL‐13Rα2 CAR‐T cells with no effect on cytokine release. By increasing the expression of S1P1, GAS encouraged the entry of CAR‐T cells into the brain and bone marrow. Transcriptomic analysis revealed that genes related to skeletal migration such as add2 and gng8 showed increased expression in GAS‐treated CAR‐T cells. We found that GAS synergistically improves the mobility of IL‐13Rα2 CAR‐T, enhancing their ability to recognize the tumor antigen of glioblastoma, which could be advantageous for the application of CAR‐T for the treatment of solid tumors.


  • IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy

    by Aiqin Gu, Yue Bai, Can Zhang, Chang Xu, Zhijing An, Ying Zhang, Steven H. Zhong, Yi Hu, Xiaosong Zhong

    Chimeric antigen receptor (CAR)-modified T (CAR-T) cell therapy has been proven to be a powerful tool for the treatment of cancer, however, the limits are obvious, especially for solid tumors. Therefore, constantly optimizing the structure of CAR to improve its therapeutic effect is necessary. In this study, we generated three different third-generation CARs targeting IL13Rα2, with the same scFv, but different transmembrane domains (TMDs) from CD4, CD8 or CD28 (IL13-CD4TM-28.BB.ζ, IL13-CD8TM-28.BB.ζ and IL13-CD28TM-28.BB.ζ). CARs were transduced into primary T cells using retroviruses. The anti-GBM efficacy of CAR-T cells was monitored by flow cytometry and real-time cell analysis (RTCA) in vitro and examined in two xenograft mouse models. The differentially expressed genes related to different anti-GBM activity were screened by high throughput RNA sequencing. We observed that T cells transduced with these three CARs have similar anti-tumor activity when co-cultured with U373 cells which expressed higher IL13Rα2 but exhibited different anti-tumor activity when co-cultured with U251 cells that expressed lower IL13Rα2. All the three groups of CAR-T cells can be activated by U373 cells, but only IL13-CD28TM-28.BB.ζ CAR-T cells could be activated and expressed increased IFN-γ after co-culturing with U251 cells. IL13-CD28TM-28.BB.ζ CAR-T cells exhibited the best anti-tumor activity in xenograft mouse models which can infiltrate into the tumors. The superior anti-tumor efficacy of IL13-CD28TM-28.BB.ζ CAR-T cells was partially owing to differentially expressed extracellular assembly, extracellular matrix, cell migration and adhesion-related genes which contribute to the lower activation threshold, increased cell proliferation, and elevated migration capacity.


  • Open Access

    Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy

    by Ying Zhang, Qinghui Zhuang, Fang Wang, Can Zhang, Chang Xu, Aiqin Gu, William H. Zhong, Yi Hu, Xiaosong Zhong

    Background: Chimeric antigen receptor (CAR)-T cell therapy is a powerful adoptive immunotherapy against both B-cell malignancies and some types of solid tumors. Interleukin (IL) -15 is an important immune stimulator that may provide ideal long-term persistent CAR-T cells. However, higher base line or peak serum IL-15 levels are also related to severe toxicity, such as cytokine release syndrome (CRS), graft-versus-host disease (GVHD), and neurotoxicity. Methods: We successfully constructed CD19 specific armored CAR-T cells overexpressing IL-I5 and IL-15 receptor alpha (IL-15Ra). In vitro cell differentiation and viability were monitored by flow cytometry, and an in vivo xenograft mouse models was used to evaluate the anti-tumor efficiency and liver damage of CAR-T cells. Results: CAR-T cells overexpressing IL-15 alone demonstrated enhanced viability, retarded exhaustion in vitro and superior tumor-inhibitory effects in vivo. However, these tumor-free mice had lower survival rates, with serious liver injuries, as a possible result of toxicity. As expected, CAR-T cells overexpressing IL-15 combined with IL-15Ra had reduced CD132 expression and released fewer cytokines (IFNγ, IL-2 and IL-15) in vitro, as well as had the tendency to improve mouse survival via repressing the growth of tumor cells and keeping livers healthier compared to CAR-IL-15 T cells. Conclusions: These results indicated the importance of IL-15 in enhancing T cells persistence and IL-15Ra in reducing the adverse effects of IL-15, with superior tumor retardation during CAR-T therapy. This study paves the way for the rapid exploitation of IL-15 in adoptive cell therapy in the future.


    • 1 June 2022
      • Vol. 30  (3) , 844-850

    [Optimization of β-globin Stable Expression Using the Third Generation Lentiviral Vector for β-thalassemia Therapy].

    by Zhen Yu, Shuai Tong, Yue Bai, Xiao-Song Zhong

    To provide a research basis for a safe and effective cell therapy for β-thalassemia through optimization of HS4 region of the third generation lentiviral vector for stable expression of β-globin. The human β-globin HS4 region in the third generation lentiviral expression vector was optimized to construct the lenti-HBB, and the transcription and translation of β-globin gene were analyzed by RT-PCR and Western blot after the transduction of lenti-HBB in MEL cell line. Furthermore, the erythroid differentiation of CD34+ cells which were transduced lentiviral virus carrying human β-globin from normal human umbilical cord blood cells and peripheral blood cells of patients with β-thalassemia major were confirmed by colony formation assay, cell smear assay and flow cytometry. The safety and effectiveness of the optimized lenti-HBB were verified by NSG mouse in vivo test. The human β-globin was expressed stably in the MEL cells, and CD34+ cells from health umbilical cord blood as well as PBMC from patient with β-thalassemia major transduced with lenti-HBB could be differentiated to mature red blood cells. The β-globin expression and differentiation in CD34+ cells were demonstrated successfully in the NSG mouse for about 35 months after post-transplant. Stable β-globin expression through the optimization of HS4 from CD34+ in the third generation lentiviral vector is safe and effective for patients with severe β-thalassemia and other β-globin abnormal diseases.


  • Open Access

    Nicotinamide mononucleotide enhances the efficacy and persistence of CD19 CAR-T cells via NAD + –Sirt1 axis

    by Zhen Yu, Shuai Tong, Can Zhang, Yue Bai, Zhijing An, Chang Xu, Fang Wang, Yi Hu, Qinghui Zhuang, Xiaosong Zhong

    Chimeric antigen receptor (CAR)-modified T cells targeting antigens expressed on tumor cells have exhibited significant antitumor effects on several types of hematological malignancies, including acute myeloid leukemia, lymphoma, B cell maturation antigen, and CD19-positive acute lymphoblastic leukemia. However, several drawbacks, particularly the poor persistence, limit the use of CAR-T cell-based therapy. Nicotinamide mononucleotide (NMN), the precursor of nicotinamide adenine dinucleotide (NAD+), has been shown to reverse age-related complications and slow the aging rate by enhancing NAD+ levels in the body. However, whether NMN treatment could enhance the longevity and persistence of CAR-T cells and improve their antitumor efficacy is still unclear. In this study, we observed that NMN treatment limited differentiation and significantly increased stem cell–like memory (Tscm) and stem cell–like memory (Tcm) in CD19 CAR-T cells. In addition, both telomerase length and proliferation ability were increased, whereas apoptosis was reduced after NMN treatment of CD19 CAR-T cells. High-throughput sequencing data indicated that NMN treatment upregulated Sirt1 expression in CD19 CAR-T cells and downregulated genes downstream of Sirt1, such as NF-κB, TP53, and Bax. Animal experiments showed that NMN treated CAR-T cells exerted great antitumor efficacy in human xenografted mouse models. In conclusion, NMN enhances the efficacy and longevity of CD19 CAR-T cells via the NAD+–Sirt1 axis.


  • Open Access

    IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma

    by Chang Xu, Yue Bai, Zhijing An, Yi Hu, Can Zhang, Xiaosong Zhong


  • Open Access

    Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1

    by Zhijing An, Yi Hu, Yue Bai, Can Zhang, Chang Xu, Xun Kang, Shoubo Yang, Wenbin Li, Xiaosong Zhong

    Glioblastoma (GBM) is the most common and aggressive brain malignancy in adults and is currently incurable with conventional therapies. The use of chimeric antigen receptor (CAR) modified T cells has been successful in clinical treatment of blood cancers, except solid tumors such as GBM. This study generated two third-generation CARs targeting different epitopes of ephrin type-A receptor 2 (EphA2) and examined their anti-GBM efficacy in vitro and in tumor-bearing mice. We observed that these two types of T cells expressing CAR (CAR-T) targeting EphA2 could be activated and expanded by EphA2 positive tumor cells in vitro. The survival of tumor-bearing mice after EphA2 CAR-T cell treatment was significantly improved. T cells transduced with one of the two EphA2 CARs exhibited better anti-tumor activity, which is related to the upregulation of CXCR-1/2 and appropriate interferon-γ (IFN-γ) production. CAR-T cells expressed excessively high level of IFN-γ exhibited poor anti-tumor activity resulting from inducing the upregulation of PD-L1 in GBM cells. The combination of CAR-T cells with poor anti-tumor activity and PD1 blockade improved the efficacy in tumor-bearing mice. In conclusion, both types of EphA2 CAR-T cells eliminated 20%-50% of GBM in xenograft mouse models. The appropriate combination of IFN-γ and CXCR-1/2 levels is a key factor for evaluating the antitumor efficiency of CAR-T cells.